Compare Alcon AG (ALC) vs Air Products & Chemicals, Inc. (APD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alcon AG vs Air Products & Chemicals, Inc. — how do they compare? Alcon AG trades at $75 (market cap $36.44B), while Air Products & Chemicals, Inc. trades at $308.56 (market cap $68.88B). The key difference: Air Products & Chemicals, Inc. is the larger of the two by market cap, and Air Products & Chemicals, Inc. pays the higher dividend (2.34%). Which is the better fit depends on your goals.
| ALC | APD | |
|---|---|---|
Market Cap | $36.44B | $68.88B |
Sector | Health | Basic Materials |
52-Week High | $90.12 | $314.19 |
52-Week Low | $62.02 | $230.42 |
Enterprise Value | $40.28B | $86.06B |
Dividend Yield | 0.48% | 2.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $73.59, down slightly by 0.05% today, with a bullish technical signal from moving averages and a consensus analyst price target of $86.67 implying 17.8% upside. Recent Q2 2026 earnings beat estimates with EPS of $0.84 versus $0.77 expected, and the company raised its 2026 profitability outlook, driving positive investor sentiment. Revenue growth has been steady, reaching $10.40 billion in 2025, though net income margin dipped to 5.92%.
The outlook is positive given strong earnings beats, raised guidance, and bullish analyst ratings, but risks include elevated P/E of 57.52, high RSI levels suggesting overbought conditions, and margin pressures from rising costs. Institutional ownership trends and recent collaborations, like with RxSight, support growth, yet macroeconomic and competitive factors warrant caution.
Air Products and Chemicals (APD) trades at $304.01, down 1.35% with strong technical momentum and bullish moving averages. The company has beaten earnings estimates for three consecutive quarters, though recent profitability metrics show negative net income margin and ROE. Recent news highlights a major semiconductor supply deal in Taiwan and raised guidance, while analyst consensus remains strongly positive with a $346 price target representing 14% upside potential.
The outlook remains constructive given earnings momentum and strategic contract wins, but investors face risks from elevated valuation multiples and recent negative profitability. The stock's technical strength and institutional support provide near-term catalysts, though margin recovery and debt management will be critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Air Products & Chemicals, Inc.
Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated $10.3 billion in revenue in fiscal 2021.
Read more on APD →
